Clinical Trial Update: MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for the MIDRIXNEO-LUNG Dendritic Cell Vaccine in non-small cell lung cancer; the study at University Hospital Ghent has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MIDRIXNEO-LUNG Dendritic Cell Vaccine

Snippet

Sponsor: University Hospital, Ghent | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED